Metrics as of 10/13/2026, 06:34 PM (Berlin time), refresh in progress.
Protara Therapeutics Stock
Protara Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jesse Shefferman
- Employees
- 46
- Market cap
- $147 M
- IPO
- 22/10/2014
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate,…
Protara Therapeutics stock: price history
1D
-5.4%
1W
+2.3%
1M
-31.4%
6M
-48.9%
YTD
-50.8%
1Y
-50.9%
2Y
+56.0%
5Y
-59.4%
10Y
-99.3%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~34% weaker price swings than usual
Ask the agents about Protara Therapeutics
Analyst assessment of Protara Therapeutics
PRICE TARGET LOW
US$12.00
CONSENSUS
US$12.00
MEDIAN
US$12.00
PRICE TARGET HIGH
US$12.00
0
STRONG BUY
6
BUY
0
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 20/05/2026
Protara Therapeutics stock metrics
P/E
-1.93
P/B
0.99
EV/EBITDA
-1.91
RETURN ON EQUITY
-13.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
87.5%
FLOAT SHARES
49,157,350
AVG. DAILY VOLUME (30D)
1,348,273
Insider transactions (SEC)
Shefferman Jesse
Shefferman Jesse
Shefferman Jesse
Shefferman Jesse
Shefferman Jesse
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Protara Therapeutics stock
What does Protara Therapeutics do?
Protara Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jesse Shefferman, the company employs around 46 people.
The IPO was on 22/10/2014; the stock trades on NASDAQ under the ticker TARA.
What do analysts say about Protara Therapeutics stock?
6 analysts rate the stock, the consensus is Buy (as of 20/05/2026).
The average price target is US$12.00, ranging from US$12.00 to US$12.00, with a median of US$12.00.
This is an external assessment, not a statement by Market Jury.
When does Protara Therapeutics report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly -34% stronger than usual.
Does Protara Therapeutics pay a dividend?
No, Protara Therapeutics currently does not pay a dividend.
Which stocks are comparable to Protara Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Protara Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Protara Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.